New York, Jan 19, 2026, 14:58 (EST) — Market closed
- Philip Morris shares ended Friday up 0.6%, closing at $173.62.
- U.S. markets are closed Monday for Martin Luther King Jr. Day; regular trading resumes Tuesday.
- On Jan. 22, FDA advisers will review ZYN’s modified-risk claims; PMI plans to publish its results on Feb. 6.
Philip Morris International Inc shares ended Friday at $173.62, up $1.06, after moving between $170.76 and $174.24 on about 5.1 million shares traded. The NYSE holiday calendar notes that U.S. markets will be closed Monday in observance of Martin Luther King Jr. Day.
With no U.S. cash trading Monday, PM stock faces its real challenge when markets open Tuesday. This week holds two crucial events for the company’s smoke-free push: a U.S. regulatory review of its ZYN nicotine pouches and Philip Morris’ quarterly earnings report.
Risk sentiment swung even with the holiday slowdown. Global stocks fell as safe-haven assets climbed, following U.S. President Donald Trump’s threat of new tariffs on European nations. Economists flagged growing policy uncertainty as the key factor. “There is obviously a response (in financial markets) to the new tariff threats,” noted George Lagarias, chief economist at Forvis Mazars. Reuters
Philip Morris, based in Stamford, Connecticut, sells cigarettes as well as smoke-free products such as IQOS heated tobacco devices and ZYN nicotine pouches via Swedish Match.
On Jan. 22, the U.S. Food and Drug Administration’s Tobacco Products Scientific Advisory Committee will meet virtually from 9 a.m. to 4:30 p.m. ET. They’ll review Swedish Match’s requests for “modified risk tobacco product” orders covering several ZYN pouch flavors. Getting that modified-risk label matters since it lets companies make broader marketing claims, though the committee’s recommendations are non-binding. U.S. Food and Drug Administration
The FDA has approved 20 ZYN nicotine pouch products for U.S. sale via its premarket review process, but the modified-risk tobacco product (MRTP) application remains a distinct challenge. The agency’s ZYN MRTP page states that public comments related to the Jan. 22 meeting must be submitted by 11:59 p.m. ET on Jan. 21.
Philip Morris is set to report its full-year and Q4 2025 results on Feb. 6 at 9 a.m. EST, according to its investor-relations calendar. Investors will be watching closely for updates on pricing tactics, cost developments, and the growth pace of its smoke-free segment as 2026 nears.
Philip Morris is counting down to a new borrowing stage. According to a December filing, the company locked in a $2.0 billion senior unsecured revolving credit facility, effective Jan. 29, which will replace its existing facility. The credit line is earmarked for general corporate purposes.
That said, risks linger. Regulators could tighten restrictions on nicotine products. If advisory panels resist or February sales disappoint, Philip Morris’s schedule for phasing out cigarettes might face significant delays.
PM plans to restart live trading on Tuesday. The FDA will review ZYN’s modified-risk applications on Jan. 22, with the company’s earnings report and outlook coming up Feb. 6.
